Welcome to the Medicines Patent Pool (MPP) support page. We are a Geneva-based public health organisation dedicated to securing voluntary licensing as a way of driving down the costs of essential medicines and health technologies in low- and middle-income countries (LMICs). These lower costs mean greater access to life-saving scientific advancements for those who need them most – but we need YOUR help to get there.
By 2035, together we can achieve:
In this video, Charles Gore, Executive Director of MPP, calls for support to further scale MPPs impact and ensure equitable global health.
Millions in low- and middle-income countries face urgent health challenges. Nearly 2 billion people lack access to the medicines they need, undermining individual well-being, health system resilience, and global health security.
MPP provides sustainable solutions that save millions of lives and by December 2024, 1.9 million deaths had been averted through the use of MPP-licensed products. With limited funds, MPP has saved the global health community US$ 10 billion in theoretical expenses (the value of using MPP-licensed products and their resulting health impacts).
Since our founding by Unitaid in 2010, MPP has delivered 52 billion treatment doses in 148 countries, saving the global health community US$ 1.9 billion. 23 million people living with HIV in LMICs have access to affordable, high-quality generic medicines thanks to an MPP licence negotiated in 2014 for the WHO-recommended treatment of dolutegravir.
Biotherapeutics such as monoclonal antibodies are crucial for treating diseases but remain inaccessible in many LMICs. MPP is working to improve access through voluntary licensing, technology transfer and collaborations with key stakeholders.
MPP supports diversified manufacturing through licensing and facilitating technology transfer to local and regional manufacturers, contributing to improved access to health products, supply security and emergency preparedness and response.
Equitable access to countermeasures for future pandemics in LMICs must remain in focus. MPP aims to incorporate licensing and technology transfer as essential elements in the global framework for pandemic preparedness and response.
MPP collaborates closely with key partners to ensure that licensing and funding agreements for early-stage health technologies include terms that facilitate access in LMICs.
Tech transfer has been initiated to 15 mRNA Programme Manufacturing partners, of which XY have already received the technology platform training at Afrigen.
While MPP has expanded its donor base thanks to growing momentum, recent reductions in global health funding risk slowing this progress. Additional support is urgently needed to sustain and scale this critical work.
Founder & Funder since 2010
Email us at partnership@medicinespatentpool.org
Address: Rue de Varembé 7, 1202 Geneva, Switzerland